iLLUMINATE Study Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PCYC-1130-CA-00 + More Info RESOLVE Study Metastatic Pancreatic Adenocarcinoma PCYC-1137-CA + More Info PCYC-1123-CA Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) + More Info iNNOVATE Study Waldenstrӧm's Macroglobulinemia PCYC-1127-CA + More Info Solid Tumor Study Relapsed or Refractory Solid Tumors Non-Small Cell Lung Cancer (NSCLC) Breast Cancer Pancreatic Cancer PCYC-1135-CA + More Info PCYC-1128-CA Renal cell Carcinoma (RCC); Urothelial Carcinoma; Gastric Adenocarcinoma; Colorectal Adenocarcinoma (CRC) + More Info Clinical Trials - Currently Enrolling PCYC-1124-CA Clinical Trial - Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) iNNOVATE Clinical Trial - Previously treated and untreated Waldenstrom’s Macroglobulinemia RESOLVE Clinical Trial - Metastatic Pancreatic Adenocarcinoma Solid Tumor Study Clinical Trial - Relapsed or Refractory Solid Tumors (NSCLC, Breast Cancer, Pancreatic Cancer) PCYC-1123-CA - Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) PCYC-1128-CA - Renal Cell Carcinoma (RCC); Urothelial Carcinoma; Gastric Adenocarcinoma; Colorectal Adenocarcinoma (CRC) For More Information: Call 1-877-877-3536, or e-mail: email@example.com Visit ClinicalTrials.gov for a complete list and learn more information about ongoing clinical trials. The information provided herein may contain references to ibrutinib or a use of ibrutinib which has not been approved by any regulatory agency. Providing this information should not be construed as recommending the use of ibrutinib for uses which have not been approved by any regulatory agency. The safety and efficacy of the investigational use of ibrutinib has not been determined. There is no guarantee that the investigational uses listed will be filed with and/or approved for marketing by any regulatory agency. For additional information, you may visit www.clinicaltrials.gov. For products approved by any regulatory agency please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product for its approved indications.